Burgdorf – At the Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) held on 1 July 2026, the shareholders approved all proposals put forward by the Board of Directors. Dr. Simone Wyss Fedele was newly elected to the Board of Directors. Gilbert Achermann, Paul Fonteyne, Dr. Martin Münchbach, Marie-Pierre Zerr, and Simon Michel were re-elected as members of the Board of Directors, and Gilbert Achermann was also confirmed as Chairman of the Board of Directors.
The Annual General Meeting approved a doubling of the dividend to CHF 4.40 per share for the 2025/26 fiscal year (previous year: CHF 2.20 per share). This means that approximately 35 % of net profit, excluding the one-time effects from the sale of the Diabetes Care business unit and the sale of Ypsotec, will be distributed to shareholders. The dividend consists of CHF 1.70 from capital contribution reserves and CHF 2.70 from retained earnings. In addition, the shareholders approved the management report, the annual financial statements, the consolidated financial statements, and the report on non-financial matters.
Dr. Simone Wyss Fedele was elected as a new member of the Board of Directors. The Board of Directors now consists of six members.
With Dr. Simone Wyss Fedele, we are gaining an experienced leader for our Board of Directors. Her many years of experience in the life sciences industry, as well as her deep understanding of international markets and trade policy as CEO of Switzerland Global Enterprise, are valuable assets to Ypsomed’s global growth strategy,
said Simon Michel, CEO of Ypsomed, at the Annual General Meeting.
Gilbert Achermann, Paul Fonteyne, Dr. Martin Münchbach, Marie-Pierre Zerr, and Simon Michel were re-elected as members of the Board of Directors. Gilbert Achermann was also re-elected as Chairman of the Board of Directors. In addition, Gilbert Achermann, Paul Fonteyne, and Dr. Simone Wyss Fedele were re-elected and elected, respectively, as members of the Nomination & Compensation Committee.
Together with the Board of Directors, I look forward to continuing to actively shape the future of Ypsomed. Our goal is clear: We want to be the global leader in subcutaneous self-injection technology,
said Gilbert Achermann upon his re-election as Chairman of the Board of Directors.
The detailed report and additional information are available here: Annual General Meeting 2026
Ypsomed’s next Annual General Meeting will take place on Tuesday, 29 June 2027.
Press release as PDF
